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a b s t r a c t
Tetherin has been deﬁned as a restriction factor of HIV-1 and several other enveloped viruses. However,
the signiﬁcance of tetherin in viral infection remains to be further addressed. Here, we investigated
whether tetherin plays a role in HSV-2 infection. Our study revealed that overexpression of tetherin
restricted the release of HSV-2 into the extracellular medium, while knockdown of tetherin by siRNA
enhanced its release. We further demonstrated that HSV-2 infection and viral glycoproteins gB, gD, gH
and gL but not gM signiﬁcantly downregulated the endogenous expression of tetherin. Additional study
indicated that tetherin likely physically interacted with gB, gD, gH and gL. This is the ﬁrst time that
tetherin has been shown to be counteracted by multiple viral components of a virus. Our ﬁndings inform
the complexity of HSV-2-host interactions, providing basis for understanding the role of tetherin as a
viral restriction factor and the mechanisms underlying viral countermeasures.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Tetherin (BST2/CD317/HM1.24) is widely expressed in responses
to type I interferons and constitutively expressed on several cell
types, including bone marrow stromal cells, plasmacytoid dendritic
cells, terminally differentiated B cells and the apical surface of
polarized epithelial cells (Blasius et al., 2006; Rollason et al., 2009).
Its gene expression in primary cells can be induced by cellular
activation (Saraiva Raposo et al., 2013). Tetherin is a type II trans-
membrane protein (Ohtomo et al., 1999) with an unusual topol-
ogy which contains an N-terminal cytoplasmic domain, a single
membrane-spanning α-helices, an extracellular (ecto-) domain, and
a C-terminal GPI anchor (Kupzig et al., 2003). Tetherin asso-
ciates with cholesterol-enriched lipid rafts which are involved in
both virus budding and cell-to-cell spread (Gofﬁnet et al., 2009;
Kupzig et al., 2003; Rollason et al., 2009, 2007).
Tetherin was identiﬁed to be involved in the host defense against
viruses by a proteomic analysis of the plasma membrane treated
with the K5/MIR2 protein of KSHV (Bartee et al., 2006).
At that time, tetherin was thought to be involved in normal and
malignant B cell differentiation (Goto et al., 1994) and had no other
deﬁned function. In 2008, tetherin was revealed to exert antiviral
activity by the formation of tethers to capture the nascent HIV-1 viral
particles to the cell surface, thereby inhibiting viral release (Neil et al.,
2008; Van Damme et al., 2008). In addition to HIV-1, tetherin has been
reported to restrict the release of a number of enveloped viruses,
including the members of Retroviridae (HIV-2, SIV, etc), Filoviridae
(Ebola virus and Marburgvirus), Arenaviridae (Lassafevervirus), Her-
pesviridae (KSHV), Rhabdoviridae (vesicularstomatitis virus), Ortho-
myxoviridae (inﬂuenza Avirus), Paramyxoviridae (Nipahvirus) and
Flaviviridae (Dengue virus) (Douglas et al., 2010; Jouvenet et al.,
2009; Kaletsky et al., 2009; Le Tortorec et al., 2011; Mansouri et al.,
2009; Pan et al., 2012; Sakuma et al., 2009). The listed viruses
restricted by tetherin share little or no homology with one another
except a lipid envelope. To date, several viral proteins, including Vpu
(HIV-1) (Neil et al., 2008; Van Damme et al., 2008), Nef (SIV) (Jia et al.,
2009), Env (HIV-2 and SIV) (Gupta et al., 2009; Le Tortorec and Neil,
2009), K5 (KSHV) (Bartee et al., 2006; Mansouri et al., 2009), Ebola
glycoprotein (Kaletsky et al., 2009), have been revealed to counteract
the restrictive properties of tetherin.
Of interest, among the viruses restricted by tetherin, KSHV belongs
to the γ-herpesvirus subfamily. In contrast, human cytomegalovirus
(HCMV), a member of the β-herpesvirus subfamily, has been reported
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to be enhanced by tetherin at the stage of viral entry (Viswanathan
et al., 2011). Herpesviridae is a large family subdivided into three
subfamilies: α-herpesvirinae, β-herpesvirinae and γ-herpesvirinae.
Given the opposite effects of tetherin on KSHV and HCMV, we asked
whether tetherin plays a role in the infection of α-herpesviruses.
Indeed, in the process of this manuscript submission, tetherin has
been reported to restrict the release of HSV-1 with one report sugg-
esting that virion host shutoff protein was important for tetherin
counteraction (Zenner et al., 2013) and the other that tetherin was
moderately antagonized by glycoprotein M (Blondeau et al., 2013),
indicative of a greater complexity in herpesvirus–tetherin interactions.
HSV-2 is a typical member of the α-herpesvirus subfamily. It is
the predominant cause of genital herpes and its infection increases
the risk of HIV-1 acquisition and transmission (Baeten et al., 2004;
Freeman et al., 2006). In the current study, we addressed whether
tetherin plays a role in HSV-2 infection. We demonstrated that the
release of mature infectious HSV-2 particles could be signiﬁcantly
impaired by tetherin overexpression, while knockdown of tetherin
enhanced HSV-2 release. Unlike its role played in the entry of
HCMV, tetherin did not enhance HSV-2 entry. We further revealed
that HSV-2 infection and several viral glycoproteins, including gB,
gD, gH and gL, signiﬁcantly downregulated the expression of teth-
erin. Our data together demonstrate that tetherin restricts HSV-2
release. Such tetherin-mediated restrictions can be counteracted
by HSV-2 gB, gD, gH, and gL.
Results
Overexpression of human tetherin decreases the release of HSV-2
progeny virions
In the current study, we attempted to address whether tetherin
plays a role in HSV-2 infection. HSV-2 infects cervical epithelial cells.
We therefore conducted our experiments by using HeLa cells. We ﬁrst
determined HSV-2 growth kinetics in HeLa cells (Fig. S1). Although
tetherin was detected on the cell surface of untreated HeLa cells, the
level of tetherin was increased 2-fold upon treatment with IFN-α
(Fig. 1A and B). Tetherin showed several isoforms upon SDS PAGE
analysis, presumably due to heterogeneity of glycosylation during
Fig. 1. Overexpression of human tetherin decreases the release of HSV-2 progeny virions. (A) Flow cytometric analysis of cell-surface expression of tetherin on mock or IFN-α
treated HeLa cells. One representative histogram is shown with mean ﬂuorescence intensity (MFI) values obtained from three independent experiments (Po0.01). (B) The
expression of total tetherin in mock or IFN-α-treated HeLa cells was analyzed by western blot where actin was used as a loading control. Molecular weight standards in
kilodaltons are shown on the left. The relative expression levels of tetherin to actin are shown. (C) Mock or IFN-α treated HeLa cells (2105 per well) were plated onto 12-
well plates overnight. HeLa monolayers were infected with HSV-2 at an MOI of 5 PFU/cell in which 0.35 ml virus suspension per well was added to 12-well plates followed by
a 3 h of incubation and the supernatants were collected at 24 hpi. The amount of infectious cell-free virions was measured by plaque assay. (D) The expression of total
tetherin in pcDNA3.1 or pBST2-transfected HeLa cells was analyzed by western blot where actin was used as a loading control. The relative expression levels of tetherin to
actin are shown. (E–H) HeLa cells (2105 per well) were plated onto 12-well plates overnight. HeLa monolayers transfected with pcDNA3.1 or pBST2 were infected with
HSV-2 at an MOI of 5 or 1 PFU/cell in which 0.35 ml virus suspension per well was added to 12-well plates followed by a 3 h of incubation and the supernatants and infected
cells were collected at different time points. The supernatant viruses (SV) and cell-associated viruses (CV) were measured by plaque assay. The titers of CV were from
duplicate cultures in which the cells were treated or untreated with the pH3.0 citrate buffer before harvesting. One representative experiment out of three is shown (A, B and
D). Data shown are mean7SD of three independent experiments with each condition performed in triplicate (C and E–H).
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post-translational modiﬁcation (Ohtomo et al., 1999). These results
were consistent with previous reports that the expression of tetherin
could be enhanced by type I IFNs (Blasius et al., 2006). Following HSV-
2 infection of IFN-α-treated or untreated HeLa cells at a multiplicity of
infection (MOI) of 5 PFU/cell, supernatants were collected at 24 h post
infection (hpi), and thereafter, the amount of infectious cell-free
virions was analyzed using plaque assays. Compared to untreated
cells, the release of HSV-2 progeny virions were severely reduced in
the IFN-α-treated cells. In particular, treatment with 500 U/ml of IFN-α
resulted in an approximate 14-fold reduction in the yield of infectious
HSV-2 particles (Fig. 1C). Given that other cellular components induced
by IFN-α may also inhibit the replication of HSV-2, we next deter-
mined whether overexpression of tetherin accounted for the reduced
release of HSV-2 progeny virions. HeLa cells were transfected with
tetherin expression plasmid (pBST2) or pcDNA3.1 prior to HSV-2
infection, and the expression level of tetherinwas detected by western
blot (Fig. 1D). Following HSV-2 infection at an MOI of 5 or 1 PFU/cell,
the amount of infectious cell-free virions and cell-associated progeny
virions was analyzed at different time points. Compared to pcDNA3.1-
transfected cells, the production of supernatant viruses (SV) was
decreased 3.3-fold at an MOI of 5 PFU/cell (24 hpi) and 3.6-fold
at anMOI of 1 PFU/cell (36 hpi) in tetherin overexpressing cells (Fig. 1E
and F). Considering that cell-associated viruses (CV) likely contained
both intracellular viruses and extracellular viruses attached to the cell
surface, we then used low pH citrate buffer which can inactivate
virions on the cell surface but not intracellular ones. The titeres of CV
in duplicate cultures in which the cells were treated or untreated with
the pH3.0 citrate buffer before harvesting were tested. As shown in
Fig. 1 G and H, the amount of infectious cell-associated viruses from
citrate treated cultures decreased compared to that from citrate
untreated cultures, in particular at 24 hpi with an MOI of 5 PFU/cell
or at 36 hpi with an MOI of 1 PFU/cell, indicating that some of the
viruses were extracellular but still attached to the cell surface. More-
over, such decrease was more apparent in the tetherin overexpressing
cells. The total virus yields (SVþCV) were not signiﬁcantly changed by
overexpressing tetherin. Given the role of tetherin as a restriction
factor in inhibiting the release of enveloped viruses, our data together
suggest that overexpression of tetherin restricts the release of HSV-2.
Downregulation of endogenous tetherin expression enhances the
release of HSV-2 progeny virions
The decreased release of HSV-2 progeny virions appeared to be
associated with the increased levels of tetherin expression, suggesting
that tetherin is likely to be an effective restriction factor of HSV-2
release. To examine whether endogenous tetherin can reduce the
release of HSV-2 progeny virions, HeLa cells were transfected with
tetherin siRNA or control siRNA prior to HSV-2 infection. Flow
cytometry analysis indicated that siRNA knockdown of tetherin
resulted in a reduction of cell-surface expression of tetherin in
80% cells (Fig. 2A). The total tetherin level was also signiﬁcantly
decreased as demonstrated by western blot analysis and the siRNA
effect remained apparent up to 96 h post transfection (Fig. 2B). siRNA-
pretreated HeLa cells were subsequently infected with HSV-2 at an
MOI of 5 or 1 PFU/cell, and the amount of infectious cell-free viruses
was determined at different time points. Compared to control siRNA-
pretreated cells, the release of infectious HSV-2 progeny virions was
increased 4.6-fold at an MOI of 5 PFU/cell (24 hpi) and 5.9-fold at
an MOI of 1 PFU/cell (36 hpi) in tetherin siRNA pretreated cells (Fig. 2C
and E). The titers of CV in duplicate cultures in which the cells were
treated or untreated with the pH3.0 citrate buffer before harvesting
were also tested. As shown in Fig. 2D and F, the amount of infectious
cell-associated viruses from citrated treated cultures decreased com-
pared to that from citrate untreated cultures, in particular at 24 hpi
with an MOI of 5 PFU/cell or at 36 hpi with an MOI of 1 PFU/cell,
indicating that some of the viruses were extracellular but still attached
to the cell surface. Such decrease in the control siRNA pretreated cells
was more apparent than that in the tetherin siRNA pretreated cells.
And the total virus yields (SVþCV) were not signiﬁcantly changed by
downregulating tetherin expression. The correlation between the dose
of tetherin siRNA, the expression level of tetherin and the production
of HSV-2 progeny virions was further examined. As shown in Fig. 2G
and H, the increased dose of tetherin siRNA positively correlated with
the production of supernatant viruses and negatively correlated with
the expression level of tetherin, indicating a negative association
between tetherin expression and HSV-2 release.
Lower expression of tetherin associated with higher amount of
infectious progeny virions, indicating that tetherin unlikely enh-
ances HSV-2 entry. To further conﬁrm the observation, we monitored
whether the immediate early events of HSV-2 infection were
inﬂuenced by tetherin. HeLa cells were transfected with tetherin
siRNA or control siRNA followed by HSV-2 infection at an MOI of
5 PFU/cell. At different time points, cells were collected and the RNA
expression of HSV-2 IE protein (ICP4) was detected by relative
quantitative RT-PCR. According to 2ΔΔCT method, the fold change
in target gene expression is normalized to an endogenous reference
gene. For the control sample, 2ΔΔCT equals to one (Livak and
Schmittgen, 2001). In terms of HSV-2 ICP4 RNA expression, the mean
fold change of HeLa cells pretreated with tetherin siRNA relative to
the control was around one (Fig. 2I), indicating that there was no
Fig. 2. Downregulation of endogenous tetherin expression enhances the release of HSV-2 progeny virions. (A) Flow cytometric analysis of tetherin cell-surface expression on
HeLa cells pretreated with tetherin siRNA or control siRNA at 24 h post transfection. (B) The expression of total tetherin in HeLa cells pretreated with tetherin siRNA or control
siRNA was analyzed at different time points by western blot where actin was used as a loading control. Molecular weight standards in kilodalton are shown on the left. (C–F)
Tetherin siRNA or control siRNA pretreated HeLa cells (2105 per well) were plated onto 12-well plates overnight. HeLa monolayers were infected with HSV-2 at an MOI of
5 or 1 PFU/cell in which 0.35 ml virus suspension per well was added to 12-well plates followed by a 3 h of incubation. Supernatants and infected cells were collected at
different time points, and the supernatant viruses (SV) and cell-associated viruses (CV) were measured by plaque assay. The titers of CV were from duplicate cultures in which
the cells were treated or untreated with the pH3.0 citrate buffer before harvesting. The dose of siRNA used in (A–F) was 250 ng/well. (G) Correlation between the production of
HSV-2 progeny virions and the dose of tetherin siRNA. HeLa cells (2105 per well) were plated onto 12-well plates overnight. HeLa monolayers pretreated with different
doses of tetherin siRNAwere infected with HSV-2 at an MOI of 5 PFU/cell inwhich 0.35 ml virus suspension per well was added to 12-well plates followed by a 3 h of incubation.
Supernatants and infected cells were collected at 24 hpi, and the supernatant viruses (SV) were measured by plaque assay. Spearman test was applied and the spearman r and p
value are shown. (H) Correlation between the expression level of tetherin and the dose of tetherin siRNA. (I) HeLa cells (3.5105 per well) were plated onto 12-well plates
overnight. HeLa monolayers pretreated with tetherin siRNA or control siRNA for 24 h were infected with HSV-2 at an MOI of 5 PFU/cell in which 1 ml virus suspension per well
was added to 12-well plates followed by a 1 h of incubation. At 2, 8 and 24 hpi, the RNA expression of HSV-2 IE protein (ICP4) in cells was measured by relative quantitative RT-
PCR. The difference in ICP4 RNA expression was calculated on the basis of 2ΔΔCT values. (J) The protein expression level of ICP4 (parallel samples in (I)) was measured by
western blot. (K) HeLa cells (2105 per well) were plated onto 12-well plates overnight. HeLa monolayers pretreated with tetherin siRNA or control siRNA for 24 h were
infected with HSV-2 at an MOI of 5 PFU/cell (0.35 ml per well in 12-well plates). At 0, 10, 20, 30 and 45 min post infection, cells were harvested and the protein expression level
of ICP5 was measured by western blot. (L) HeLa cells (parallel samples in (K)) were treated for 2 h with DNase-I and viral genomic DNA isolated and intracellular HSV-2 genome
copy number enumerated by quantitative Taqman PCR speciﬁc for gB. The probe was labeled at the 50 end with FAM and at the 30 end with TAMRA. Values are presented as
copies/ng DNA (HSV-2 episomes per nanogram of total cellular DNA). (M) HeLa cells (2105 per well) were plated onto 12-well plates overnight. HeLa monolayers pretreated
with tetherin siRNA or control siRNA for 24 h were infected with HSV-2 at different MOIs (0, 0.1, 1, 3, 5 PFU/cell) inwhich 0.35 ml virus suspension per well was added to 12-well
plates followed by a 3 h of incubation. At 24 hpi, intracellular HSV-2 genome copy was measured as (L). (N) HeLa cells (parallel samples in (M)) were harvested and the protein
expression level of ICP5 was measured by western blot. Data shown are mean7SD of three independent experiments with each condition performed in triplicate (C–G, I, L and
M). One representative experiment out of three is shown (A, B, H, J, K and N).
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difference in ICP4 RNA expression between HeLa cells pretreated
with tetherin siRNA and those pretreated with control siRNA. We
also examined the protein expression of viral immediate early gene
(ICP4) (at 8 and 24 hpi) in the infected cells by western blot. The
expression level of ICP4 in HeLa cells pretreated with tetherin siRNA
was similar to that pretreated with control siRNA (Fig. 2J). At the
same time, the genomic DNA and protein from incoming viruses
were detected at several time points (0, 10, 20, 30, 45 min) post
infection. As shown in Fig. 2K and L, the copies of HSV-2 genomic
DNA and the protein level of HSV-2 major capsid protein (ICP5) in the
tetherin siRNA pretreated HeLa cells showed no difference compared
to those in the control siRNA pretreated HeLa cells at 10, 20, 30,
45 min post infection. In addition, the intracellular copies of HSV-2
genome and the protein expression of late gene (ICP5) were
determined at 24 hpi using different MOIs (0, 0.1, 1, 3, 5 PFU/cell).
As shown in Fig. 2M and N, HSV-2 genome level remained constant
and there was no difference in ICP5 expression in the cells pretreated
with tetherin siRNA or control siRNA. These results further support
the notion that tetherin has no effect on HSV-2 gene expression. Our
data together imply that tetherin does not enhance HSV-2 entry and
replication. In conclusion, downregulation of endogenous tetherin
expression enhances the release of HSV-2 progeny virions.
Given our current knowledge of tetherin as an anti-viral protein
that tethers virions to cell membranes, we hypothesized that
tetherin might decrease the release of HSV-2 progeny virions
through a similar mechanism. We therefore examined the associa-
tion of HSV-2 virion particles with the cell membranes of HeLa cells
pretreated with tetherin or control siRNA by electronic microscopy.
Large-scale surface clustering of mature HSV-2 virions was seen in
the control siRNA-pretreated cells (Fig. 3B and E), whereas single or
small clusters of virions were observed in association with the cell
membranes of tetherin siRNA-pretreated cells (Fig. 3A and D),
indicating that more particles were released to medium in teth-
erin-knocked down cells as measured by infectivity assays (Fig. 2C
and E). Statistically, there was an approximately 6–7 fold greater
density of mature particles on the surface of control siRNA-
pretreated cells compared to the tetherin siRNA-pretreated cells
(Fig. 3C and F). To determine whether tetherin was incorporated
into HSV-2 virions, we fractionated virion preparations via a sucrose
gradient cushion to separate cellular membrane fragments and
defective viral particles from intact infectious virions. The repre-
sentative viral and cellular proteins were examined by western blot.
As shown in Fig. 4A, HSV-2 major capsid protein VP5 (ICP5) was
detected in fractions 5–11 while envelope glycoprotein gB was
mainly presented in fractions 8–11. Among those fractions, only
fractions 8–11 infected Vero cells and had plaque formation,
suggesting that intact infectious HSV-2 virions mainly existed in
fractions 8–11. We also examined the presentation of CD326, an
epithelial cells marker, and tetherin. CD326 was detected in the
fractions 5–7, indicating that cellular components mainly existed in
low density fractions. In agreement, tetherin was also detected in
fractions 4–7, and peaked in fractions 5 and 6. Of note, a small
amount of tetherin was detected in fractions 8–11, suggesting that
tetherin is likely to be present in HSV-2 virions. To further conﬁrm
the observation in fraction assays, harvested HSV-2 virions were
applied to poly-L-lysine coated coverslips and analyzed by immu-
noﬂuorescence microscopy. A representative ﬁeld observed is
shown in Fig. 4B. The FITC-positive dots that were positive for
tetherin colocalized with the Cy3-positive dots that were positive
for HSV-2 ICP5. The ﬂuorescence colocalization of tetherin and ICP5
indicated that tetherin might be incorporated into HSV-2 virion.
HSV-2 infection downregulates the expression of tetherin
To investigate whether HSV-2 infection can inﬂuence the
expression of tetherin, cell surface expression of tetherin in the
presence or absence of HSV-2 infection was examined by ﬂow
cytometry at 24 hpi. Compared to that on uninfected cells, the
expression of tetherin on HSV-2 infected HeLa and ME-180 cells
was remarkably diminished (Fig. 5A). We also examined tetherin
expression on primary mucosal epithelial cells isolated from
cervical explants using previously established methods (Howell
et al., 1997; Hu et al., 2004; Huang et al., 2012). As shown in
Fig. 5A, the expression level of tetherin on primary epithelial cells
was increased after treatment with IFN-α for 24 h. Following HSV-
2 infection, the expression of tetherin was remarkably decreased
in primary epithelial cells. In addition to ﬂow cytometry analyses,
we also examined total protein expression by western blot. As
shown in Fig. 5B and C, cells infected with HSV-2 showed a
signiﬁcant decrease of total tetherin protein. As a cell membrane
protein control, the epithelial marker CD326 was analyzed paral-
lelly and its expression appeared to be the same in samples with
or without HSV-2 infection. Collectively, we conclude that HSV-2
infection can efﬁciently downregulate the expression of tetherin.
Multiple HSV-2 glycoproteins contribute to the downregulation of
tetherin expression
The “tethered” virions observed in electron microscopy images
were fully mature and had complete and intact outer membranes,
implying interactions between the molecules on cell and virion
exteriors. We hypothesized that some of HSV-2 viral envelope
glycoproteins might mediate an interaction between virion and
tetherin. Considering that envelope glycoproteins (gB, gD, gH, and
gL) are essential for HSV entry (Caiet al., 1988; Cheshenko and
Herold, 2002; Desai et al., 1988; Hutchinson et al., 1992; Ligas and
Johnson, 1988; Muggeridge, 2000), we focused on gB, gD, gH, and gL
to address their potential roles played in the counteraction of
tetherin. We examined HSV-2 gM because the gM of HSV-1 has
recently been shown to moderately antagonize tetherin. We also
examined glycoproteins gE and gG. To deﬁne the mechanisms by
which HSV-2 downmodulates tetherin expression, HeLa cells were
transfected with plasmid expressing gB-ﬂag, gD-ﬂag, gH-ﬂag, gL-
ﬂag, gE-ﬂag, gG-ﬂag gM-ﬂag, or control plasmid pcDNA3.1. At 48 h
post transfection, cells were harvested and the cell-surface expres-
sion of tetherin was examined by ﬂow cytometry. Compared to
pcDNA3.1-transfected cells, the cell-surface expression of tetherin
was signiﬁcantly decreased in gB, gD, gH, or gL-transfected cells
whereas the expression of tetherin in gM, gE or gG transfected cells
remain unchanged (Fig. 6A). The parallel cell lysates were analyzed
by western blot. In accordance with the ﬂow cytometry assay,
tetherin was signiﬁcantly decreased in cells transfected with plas-
mid expressing gB-ﬂag, gD-ﬂag, gH-ﬂag or gL-ﬂag, but not in those
transfected with gM-ﬂag (Fig. 6B), suggesting that gB, gD, gH and gL
could speciﬁcally downmodulate tetherin. The expression of gB-ﬂag,
gD-ﬂag, gH-ﬂag, gL-ﬂag and gM-ﬂag was conﬁrmed (Fig. 6C). The
epithelial marker CD326 was analyzed parallelly as a cell membrane
protein control, and was unaffected by viral glycoproteins compared
to tetherin (Fig. 6B and C). These data collectively suggest that HSV-2
envelope glycoproteins highly likely account for the downmodula-
tion of tetherin during HSV-2 infection.
gB, gD, gH, and gL physically interact with tetherin
To further conﬁrm the speciﬁcity, we next investigated whether
there was a physical interaction between tetherin and gB, gD, gH or
gL. The cellular localization of tetherin and HSV-2 glycoproteins was
detected by immunoﬂuorescence assay. The cellular localization of a
protein can be altered by its interacting proteins (Liu et al., 2009).
Therefore, we examined the localization of HSV-2 glycoproteins in
293T cells which have no endogenous tetherin expression (Fig. S3).
Images showed that gB-ﬂag and gD-ﬂag were detected on the cell
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surface of permeabilized or non-permeabilized cells. In addition, the
cellular localization of untagged HSV-2 glycoproteins gB and gD in
transfected cells was consistent with that of ﬂag-tagged gB and gD
(Fig. S2). In contrast, gH-ﬂag and gL-ﬂag were only detected in
permeabilized cells (Fig. S3), informing that gH-ﬂag and gL-ﬂag
expressed independently failed to be transported to the cell surface.
Nevertheless, similar to gB-ﬂag and gD-ﬂag, both gH-ﬂag and gL-ﬂag
demonstrated colocalization with tetherin in the transfected cells
(Fig. S3). The colocalization of tetherin and the viral glycoproteins in
HeLa cells was also examined. As shown in Fig. 7, the colocalization
of the viral glycoproteins and tetherin in HeLa cells was consis-
tent with that in 293T cells. We further cotransfected plasmids
expressing gH-ﬂag and gL-ﬂag (or gH and gL) into HeLa cells and
assessed their cellular localization. As shown in Fig. S4A, the gH-ﬂag-
gL-ﬂag complex and gH-gL complex had similar cell surface localiza-
tion. The surface expression of tetherin was also determined in cells
Fig. 3. Association of HSV-2 virion particles with cell membranes. Tetherin siRNA or control siRNA pretreated HeLa cells (3.5105 per well) were plated onto 12-well plates
overnight. HeLa monolayers were infected with HSV-2 at an MOI of 3 PFU/cell in which 1ml virus suspension per well was added to 12-well plates followed by a 1 h of incubation. At
24 or 48 hpi, infected cells were harvested and cell sections were prepared for electron microscopy. Images show the accumulation of mature HSV-2 virions adhered to the surface of
HeLa cells pretreated with control siRNA (B and E) or tetherin siRNA (A and D). Scale bars in all panels represent 500 nm. (C) Quantitative analysis of mature particles on the surface of
tetherin or control siRNA-pretreated cells at 24 hpi. (F) Quantitative analysis of mature particles on the surface of tetherin or control siRNA-pretreated cells at 48 hpi. The images were
chosen randomly, and 10 images were obtained in each condition. One representative image out of 10 is shown (A, B, D and E). The number of particles was obtained from 10
individual cells. Data shown are mean7SD of three independent experiments with each condition performed in triplicate (C and F).
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expressing gH-ﬂag-gL-ﬂag or gH-gL complexes by ﬂow cytometry. In
both cases, a similar down-regulation of tetherin was observed and
such down-regulation was comparable to that seen in cells trans-
fected with gH or gL alone (see Fig. S4B). These data together suggest
a physical interaction between tetherin and gB, gD, gH or gL. Co-
immunoprecipitation assay was performed to further conﬁrm these
ﬁndings. HeLa cells were transfected with control pcDNA3.1 or
plasmid expressing gB-ﬂag, gD-ﬂag, gH-ﬂag, gL-ﬂag or gM-ﬂag.
48 h post transfection, precleared cell lysates from the transfected
cells were incubated with an isotype control antibody and an anti-
ﬂag antibody. The precipitates were analyzed by western blot using
an antibody against tetherin, while the precleared cell lysates were
analyzed by western blot using the anti-ﬂag antibody. As shown in
Fig. 8A, the antibody against ﬂag was able to speciﬁcally precipitate
the immune complex that contained tetherin and gB-ﬂag, gD-ﬂag,
gH-ﬂag or gL-ﬂag. Co-IP experiments were also performed by pulling
downwith the anti-tetherin antibody, followed by western blot with
the anti-ﬂag or anti-tetherin antibody. The antibody against tetherin
was able to speciﬁcally precipitate the immune complex that con-
tained tetherin and gB-ﬂag, gD-ﬂag, gH-ﬂag or gL-ﬂag (Fig. 8B). The
precipitates treated with the isotype control antibody were also
analyzed by western blot with the anti-ﬂag or anti-tetherin antibody
(Fig. 8C) and there was no corresponding bands observed. The
expression of tetherin in transfected cells was analyzed by western
blot (Fig. 8D) and immunoﬂuorescence (Fig. 7), conﬁrming its correct
expression in terms of protein size and subcellular localization. The
results together conﬁrmed that there was a physical interaction
between tetherin and gB, gD, gH and gL, respectively.
Discussion
The signiﬁcance of tetherin in viral infection remains to be
further addressed. In the current study, we investigated whether
tetherin plays a role in the infection of α-herpesvirus HSV-2. Like
the γ-herpesvirus KSHV, HSV-2 progeny viral particles can be
trapped by tetherin. Unlike its role in β-herpesvirus HCMV
infection, tetherin does not enhance HSV-2 entry. Of note, HSV-2
infection signiﬁcantly downregulates the expression of tetherin
and multiple HSV-2 glycoproteins account for such downregula-
tion. Our ﬁndings that tetherin plays a key role in inhibiting the
release of HSV-2 virions support the notion that tetherin is a
broad-spectrum restriction factor of enveloped viruses (Douglas
et al., 2010). To date, viruses found to be restricted by tetherin
share little or no homology with one another except for a lipid
envelope, making it difﬁcult to forecast the effect of tetherin on
different viruses. The results in this study together provide an
initial understanding on the inhibitory effect of tetherin against
HSV-2. It is probable that tetherin may have multifaceted function
on different viruses, and this notion will remain uncertain until
more enveloped viruses have been investigated to address the
roles of tetherin in viral infection and spread.
Tetherin has an unusual topology with both ends embedded in
the cellular membrane by two different types of membrane anchor:
a transmembrane domain proximal to the N-terminus and a C-
terminal GPI anchor (Kupzig et al., 2003). It is hypothesized that
tetherin tethers virions to cell membranes, and to each other by
linking the viral envelope with the cell membrane through each of
its membrane domains or through dimers that formed between
virion-associated tetherin and tetherin in the cell membrane
(Perez-Caballero et al., 2009). Recently, Venkatesh et al. have shown
that HIV-1 virion tethers are composed of the tetherin protein itself
and that the axially conﬁgured tetherin homodimers are directly
responsible for trapping virions at the cell surface (Venkatesh and
Bieniasz, 2013). In favor of the above model, our data suggest that
tetherin is likely to be incorporated into HSV-2 virions. Electron
microscopy showed that HSV-2 virion particles associated with the
cell membranes of HeLa cells and that more virions were seen in
the control siRNA-pretreated cells than the tetherin siRNA-pre-
treated cells, while infectivity assays demonstrated that more
virions were released into the medium in tetherin-knocked down
cells. These data together suggest that cell surface expression of
tetherin appears to inhibit HSV-2 release. Flow cytometry assay
showed that HSV-2 infection downregulated tetherin expression on
Fig. 4. Tetherin is highly likely to be incorporated into HSV-2 virions. (A) HSV-2 virion preparations were fractioned via a sucrose gradient cushion (10–50%) to separate
cellular membrane fragments and defective viral particles from intact infectious virions. The representative viral and cellular proteins were assessed by western blot. One
representative experiment out of three is shown. (B) Immunoﬂuorescence analysis of HSV-2 virions. Virions harvested from HSV-2 infected HeLa cells were pelleted and
applied to poly-L-lysine-coated coverslips prior to immunoﬂuorescence analysis using anti-ICP5 and anti-tetherin antibodies. The FITC-positive dots were positive for
tetherin and the Cy3-positive dots were positive for HSV-2 ICP5. Representative ﬁelds observed in two experiments are shown. Scale bars represent 500 nm.
Y. Liu et al. / Virology 475 (2015) 96–109102
the cell surface. On the one hand, the cell surface expression of
tetherin inhibits HSV-2 release. On the other hand, HSV-2 antoga-
nizes the restriction of host cell by decreasing the expression of
tetherin. Since tetherin is a protein that recycles between the cell
surface and intracellular compartments (Kupzig et al., 2003), teth-
erin downregulated by HSV-2 infection can be supplied from the
intracellular compartments. A balance may exist between HSV-2
countermeasures and tetherin restriction. This is likely to be one of
the reasons that we can still detect a large amount of cell-associated
viruses by electron microscopy.
The “tethered” HSV-2 virions were fully mature and closely to
the cell surface or to each other, suggesting that the interactions
were mediated by tetherin and the molecules on the virion exterior.
We investigated several proteins in the outermost part, including
glycoproteins gB, gD, gH, gL and gM. These viral proteins are
transmembrane proteins and required for the interaction between
virus and the host cell. Our ﬂow cytometry data showed that several
glycoproteins (gB, gD, gH and gL) distinctly downregulated tetherin
from cell surface, indicating that tetherin is likely counteracted by
multiple HSV-2 proteins. This notion was further strengthened by
the results that several HSV-2 glycoproteins, including gB, gD, gH
and gL, physically interacts with tetherin. Of interest, although gH
and gL expressed independently failed to be transported to the cell
surface, each of them alone colocalized with tetherin and down-
regulated the expression of tetherin. Moreover, coexpression of gH
and gL resulted in the downregulation of tetherin similar to that of
gH or gL alone. To date, most of the reported tetherin antagonists,
including Vpu (HIV-1), Nef (SIV), K5 (KSHV), Env (HIV-2 and SIV),
Ebola glycoprotein (Ebola virus) are membrane-associated proteins
or phosphoproteins (Bartee et al., 2004; Chan and Kim, 1998; Cullen,
1994; Strebel et al., 1988). It seems that different viruses have
evolved different strategies to counteract tetherin restriction. Of
interest, among the reported envelope viruses restricted by tetherin,
only one tetherin antagonist has been revealed in each virus. Given
the size and proportion of HSV-2 genome likely accounted for
immune evasion, it is probable that the interaction between
tetherin and HSV-2 involves a more complex procedure. More
recently, two groups report the effect of tetherin on HSV-1 release.
Zenner et al. reported that virion host shutoff protein was important
for tetherin counteraction (Blondeau et al., 2013), whereas Blondea
et al. showed that tetherin was moderately antagonized by glyco-
protein M (Blondeau et al., 2013), implicating that tetherin is likely
counteracted by more than one HSV-1 component. Although HSV-2
is different from HSV-1, their data together reinforce our conclusion
that tetherin is counteracted by multiple viral components of HSV-
2. Likewise, HIV-1 Vpu has been shown to downregulate tetherin
Fig. 5. HSV-2 infection downregulates the expression of tetherin. HeLa cells (3.5105) were plated onto 12-well plates overnight, and then the monolayers were infected
with HSV-2 at an MOI of 5 or 1 PFU/cell in which 1 ml virus suspension per well was added to 12-well plates followed by a 1 h of incubation. (A) Flow cytometric analysis of
tetherincell-surface expression on HeLa, ME-180 and IFN-α pretreated primary epithelial cells in the presence or absence of HSV-2 infection. Cells were stained with anti-
tetherin antibody (red, purple or green line) or isotype-matched control IgG (gray line). (B) The expression of total tetherin and CD326 in mock, HSV-2 infected HeLa cells at
24 hpi was analyzed by western blot where actin was used as a loading control. The relative protein level of tetherin was normalized by that of actin. One representative
experiment out of three is shown. (C) The expression of total tetherin and CD326 in mock, IFN-α pretreated or IFN-α pretreated plus HSV-2 treated primary epithelial cells at
24 hpi was analyzed by western blot where actin was used as a loading control. The relative protein level of tetherin was normalized by that of actin. One representative
experiment out of three is shown.
Y. Liu et al. / Virology 475 (2015) 96–109 103
expression whereas Ebola GP seems to counteract tetherin without
removing it from the cell surface (Kuhl et al., 2011), suggesting that
different viral antagonists employ different mechanisms to counter-
act tetherin restriction.
In addition to gM, we have identiﬁed other glycoproteins (gE
and gG) that do not affect tetherin expression. Given the complexity
of HSV-2 genome containing over 70 genes, we cannot completely
rule out the involvement of other HSV-2 components that may also
contribute to the degradation of tetherin. Considering that HSV-2
infection is associated with an increased risk of HIV-1 acquisition
and that both viral infections can downregulate the expression of
tetherin, while beyond the scope of this study, it will be interesting
to address the biological signiﬁcance of tetherin in mucosal infec-
tion when an appropriate co-infection model becomes available.
Nevertheless, our study has demonstrated that tetherin restricts the
release of cell-free HSV-2 progeny viral particles, whereas HSV-2
infection in turn downmodulates the endogenous expression of
tetherin to facilitate viral release. Unlike other tetherin antagonists,
multiple HSV-2 glycoproteins, in particular gB, gD, gH, and gL,
physically interact with tetherin. Our ﬁndings inform the compl-
exity of HSV-2-host interactions, providing basis for further under-
standing the role of tetherin as a vrial restriction factor and the
mechanisms underlying viral countermeasures.
Conclusions
We have demonstrated that tetherin can restrict the release of
infectious HSV-2 virus particles into the extracellular medium and
that HSV-2 infection and viral glycoproteins gB, gD, gH and gL but
not gM downregulate the endogenous expression of tetherin. This
is the ﬁrst time that tetherin has been shown to be counteracted
by multiple viral components of a virus. Our ﬁndings inform the
complexity of HSV-2-host interactions, providing basis for further
understanding the role of tetherin as a viral restriction factor and
the mechanisms underlying viral countermeasures.
Materials and methods
Virus and cells
HSV-2 (strain G) was obtained from LGC standards and propagated
in African green monkey kidney cells (Vero). Virus stock was stored at
80 1C before used for infection. Human cervical epithelial cell
lines HeLa and ME-180, and embryonic kidney cell line 293T were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco)
containing 10% FBS, 100 U/ml penicillin and 100 U/ml streptomycin
at 37 1C in 5% CO2. Human cervical tissues were obtained from the
Fig. 6. Multiple HSV-2 glycoproteins downregulate the expression of tetherin. (A) Flow cytometric analysis of tetherin cell-surface expression on HeLa cells transfected with
pcDNA3.1 or plasmid expressing HSV-2 glycoprotein gB, gD, gH, gL, gE, gG or gM. Cells were stained with an anti-tetherin antibody (red or green line) or isotype-matched
control IgG (gray line). (B) Western blot was used to analyze the expression of total tetherin and CD326 in HeLa cells (parallel samples in (A)), where actin was used as a
loading control. The relative protein level of tetherin and CD326 were normalized by that of actin. (C) The expression of each glycoprotein in the transfected cells (parallel
samples in (A)) was analyzed by WB using an anti-ﬂag monoclonal antibody. One representative experiment out of three is shown.
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Fig. 7. The cellular localization of tetherin and HSV-2 glycoproteins gB, gD, gH and gL in transfected cells. HeLa cells transfected with plasmid expressing gB-ﬂag, gD-ﬂag, gH-
ﬂag or gL-ﬂag were costained with anti-ﬂag (green) and anti-tetherin (red) antibodies. Nuclei were counterstained with Hoechst 33258 (blue). Representative confocal
images from three independent experiments are shown. Scale bars in all panels represent 4 μm.
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Obstetrics and Gynecology Department at Hubei Hospital of Chi-
nese Medicine. Primary human cervical epithelial cells were iso-
lated as described previously (Howell et al., 1997; Hu et al., 2004;
Huang et al., 2012). Brieﬂy, tissues were cut into 3-mm3-mm size,
and digested by collagenase for 30 min. The separated cells were
ﬁltered through a stainless steel strainer (0.5–1.0 mm) and cultured
in complete medium for 3 h, and then the inﬂammatory cells were
discarded. Human cervical epithelial cells were cultured in 12-well
plates to 90–95% subconﬂuent before use.
All protocols involving human subjects were reviewed and
approved by the Local Research Ethics Committee. Informed written
consents from the human subjects were obtained in this study.
Plasmids
Tetherin/BST2-expressing plasmid (pBST2) was from Origene. The
ORFs of glycoproteins gB, gD, gH, gL were cloned into pcDNA3.1(þ)
(named pgB, pgD, pgH and pgL, respectively). The ORFs of glycopro-
teins gB, gD, gH, gL, gM, gE and gG with ﬂag tag fused at the C-
terminal were cloned into pcDNA3.1(þ) (named pgB-ﬂag, pgD-ﬂag,
pgH-ﬂag, pgL-ﬂag, pgM-ﬂag, pgE-ﬂag and pgG-ﬂag), respectively. The
construction, cloning and propagation of plasmids were carried out
using standard techniques (Sambrook and Russell, 2001). All con-
structs were veriﬁed by DNA sequencing (Sunny Biotechnology Co.
Ltd, Shanghai, China).
Flow cytometry
For ﬂow cytometric analysis of surface tetherin, cells were trypsi-
nized and resuspended in ﬂow cytometry buffer (1 PBS-3% fetal
bovine serum). Cells were stained for surface tetherin expression using
a phycoerythrin (PE)-conjugated antibody against tetherin (12-3179;
eBioscience). Control antibody was isotype-matched PE conjugated
IgG1 (eBiosciences). Stained cells were analyzed on a Guava Easy-Cyte
Mini (Millipore) ﬂow cytometer and data were analyzed using the
Flowjo and Summit 5.2 (Beckman Coulter) software.
siRNA mediated knockdown of tetherin
Tetherin siRNA (SI02777054) and control siRNA (1027281) were
purchased from Qiagen. HeLa cells (2105) were plated onto 12-
well plates overnight. Hela monolayers were transfected with
Fig. 8. gB, gD, gH, and gL physically interact with tetherin. HeLa cells were cotransfected with pBST2 and plasmid expressing gB-ﬂag, gD-ﬂag, gH-ﬂag, gL-ﬂag or gM-ﬂag. 48 h
post transfection, cell lysates were analyzed by co-IP. gB-ﬂag, gD-ﬂag, gH-ﬂag, gL-ﬂag or gM-ﬂag coimmunoprecipitated with tetherin was pulled down using the anti-
tetherin or anti-ﬂag antibody. (A) Immunoblot probed with an anti-ﬂag monoclonal antibody in pull-down assay between each ﬂag-glycoprotein fusion protein and tetherin.
(B) Immunoblot probed with an anti-tetherin polyclonal antibody in pull-down assay between each ﬂag-glycoprotein fusion protein and tetherin. (C) Immunoblot probed
with an isotype control antibody in pull-down assay between each ﬂag-glycoprotein fusion protein and tetherin. (D) The expression of tetherin in the transfected cells
(parallel lysates in (A) and (B)) was analyzed by WB. The relative protein level of tetherin was normalized by that of actin. One representative experiment out of three
is shown.
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tetherin siRNA or control siRNA using HiPerFect Transfection Reagent
(301704; Qiagen) according to the manufacturer’s instructions.
Viral release assay
HeLa cells were treated with or without recombinant human
IFN-α (Sigma) and cultured for a further 24 h before infection with
HSV-2 at an MOI of 5 PFU/cell. To assess the effect of tetherin on
the release of HSV-2 progeny virions, HeLa cells (2105 per
well) were plated onto 12-well plates overnight. HeLa monolayers
were transfected with pBST2 or pcDNA3.1 or pretreated with
tetherin or control siRNA. At 6 h post transfection, cells were
infected with HSV-2 at an MOI of 5 or 1 PFU/cell. At different time
points post infection, supernatants were harvested and ﬁltered.
The cell-associated viruses were harvested by freeze-thaw once
followed by sonicate in ice bucket 202 S. The virus containing
supernatants were stored at 80 1C.
To measure infectious virions released from HeLa cells, virus
containing supernatants were serially diluted and used to inoculate
Vero cells. Conﬂuent monolayers of Vero cells in 12-well plates were
infected with serially diluted HSV-2 for 1 h at 37 1C. After removal of
the inoculum and washes, 1 ml fresh medium was added, and the
cultures were incubated at 37 1C. At 48 hpi, cells were stained with
0.1% crystal violet for 5 min. Cells were thenwashed three times with
nanopure water, and the numbers of plaques were counted to
measure the release of infectious viruses. In some cases, the titers
were also determined on HeLa cells. 60% conﬂuent monolayers of
HeLa cells in 12-well plates were infected with 0.35 mL serially
diluted virus-containing supernatants for 3 h at 37 1C (Farnham,
1958). After removal of the inoculum and washes, 1 ml fresh medium
was added, and the cultures were incubated at 37 1C. At 72 hpi, cells
were stained with 0.1% crystal violet for 5 min. Cells were then
washed three times with nanopure water, and the numbers of
plaques were counted to measure the release of infectious viruses.
Viral entry assay
To assess the effect of tetherin on the entry of HSV-2 progeny
virions, HeLa cells (2105 per well) were plated onto 12-well
plates overnight. HeLa monolayers were pretreated with tetherin
or control siRNA for 24 h. The cultures were subsequently replaced
with cold (4 1C) medium and placed on ice for 10 min, followed by
the addition of precooled HSV-2 (MOI¼5 PFU/cell) and an incuba-
tion at 4 1C for 60 min. After the removal of viruses, cells were
washed twice with cold PBS and prewarmed medium (37 1C) was
added. The cultures were then shifted to 37 1C. At various time
points (0, 10, 20, 30, 45 min), the monolayers were treated with
pH3.0 citrate buffer for 1 min at room temperature followed by
twice washes with PBS. Cells were harvested and the copies of
HSV-2 genomic DNA and the levels of viral protein expression
were detected by quantitative PCR and western blot, respectively.
Isolation of extracellular virions
For the preparation of viral particles, HeLa cells were infected
with HSV-2 at an MOI of 1 PFU/cell for 2 days. Culture super-
natants were harvested and cleared by centrifugation at 1000 g
for 5 min, and then the membrane contaminants were removed
through ﬁltration using a 0.22-mm ﬁlter. The partially cleaned
virions were further puriﬁed by ultracentrifugation using sucrose
gradient cushion (10–50% in PBS) at 35,000 g for 16 h at 4 1C in a
Beckman SW40 rotor to separate viral particles from cellular
medium components. Seventeen gradient fractions were collected
for subsequent detection of cellular and viral proteins by western
blot and immunoﬂuorescence analysis.
Electron microscopy
HeLa cells (3.5105 per well) were plated onto 12-well
plates overnight. HeLa monolayers were transfected with tetherin
or control siRNA. At 6 h post siRNA transfection, cells were infected
with HSV-2 at an MOI of 3 PFU/cell, and the inoculum was
removed 1 h later. Following 24 or 48 h infection, cells were har-
vested for electron microscopy. Following ﬁxation with 2.5%
glutaraldehyde/1% paraformaldehyde in cacodylate buffer (0.1 M
sodium cacodylate [pH 7.4], 35 mM sucrose, 4 mM CaCl2), cells
were stained in 1% OsO4 and 4% uranyl acetate for 2 h, dehydrated
in a graded ethanol series (50–100%) and subsequently embedded
in epoxy resin Embed-812 (Electron Microscopy Sciences). Thin
sections (80 nm) were stained with 2% saturated uranyl acetate for
15 min, rinsed with water, and then stained with Reynolds’ lead
citrate for 15 min. Electron micrographs were taken on a Tecnai
transmission electron microscope (FEI Tecnai G2 20 TWIN) at an
accelerating voltage of 200 kV.
Quantitative PCR
For relative quantitative RT-PCR, cells were collected and the total
RNA was extracted using Trizol (Invitrogen) according to the manu-
facturer’s instructions. RNase-free DNase I (Fermentas) was used to
eliminate the contamination of genomic DNA. cDNA was then
synthesized by moloney murine leukemia virus transcriptase (Pro-
mega). The newly synthesized cDNAwas used as the template for the
ampliﬁcation of a highly speciﬁc nucleotide region of ICP4 gene. The
primers 50-GCGAGCTGCGGTTCGT-30 and 50-GCCACGCGCAGGTC-30
were used for ICP4 ampliﬁcation. GAPDH was used as an internal
control ampliﬁed with primers 50-GGGAAGCTCACTGGCATGG-30 and
50-TTACTCCTTGGAGGCCATGT-30. Relative quantitative PCR was per-
formed using a SYBR Green Real-Time PCR Master Mix (Toyobo) Dye
and an ABI stepone real-time PCR system (Applied Biosystems) as
previously described (Chen et al., 2013). The ﬁnal reaction conditions
were as follow: 95 1C for 1 min, followed by 40 cycles of 95 1C for
15 s, 60 1C for 15 s, and 72 1C for 45 s. The difference in gene
expression was calculated on the basis of 2ΔΔCT values.
For absolute quantitative PCR, cells were collected and treated for
2 h with DNase-I, and viral genomic DNA was isolated. The intra-
celluler HSV-2 genome copy number was enumerated by quantita-
tive Taqman PCR speciﬁc for gB. The probe was labeled at the 50 end
with FAM and at the 30end with TAMRA. The TaqMan Universal
Master Mix II (4427983; Applied Biosystems, Foster City, CA) was
used according to the manufacturer’s instructions. PCR was per-
formed using an ABI 7500 real-time PCR system (Applied Biosystems,
Foster City, CA). The ﬁnal 50 ml PCR system and reaction conditions
were as described previously (Aumakhan et al., 2010).
Western blot
Prepared cell lysates were resolved by 12% SDS-PAGE and
transferred to 0.45 mm polyvinylidenediﬂuoride membranes
(Millipore). Nonspeciﬁc binding was blocked using 5% non-fat
milk in PBS overnight at 4 1C. The membrane was incubated with
primary antibody against tetherin (rabbit polyclonal antibody;
11721; NIH AIDS Research and Reference Reagent Program) at a
dilution of 1:5000, ICP4 (rabbit polyclonal antibody; ab96431;
Abcam) at a dilution of 1:3000, ICP5 (mouse monoclonal antibody;
ab6508; Abcam) at a dilution of 1:3000, gB (mouse monoclonal
antibody; sc-52425; Santa Cruz) at a dilution of 1:1000, Ep-CAM
(mouse monoclonal antibody; ZM-0359; ORIGENE), HSV-2 (sheep
polyclonal antibody; PAB13979; Abnova) at a dilution of 1:2000,
FLAG (mouse monoclonal antibody; F1804; Sigma) at a dilution of
1:3000, PCNA (rabbit polyclonal antibody; 10205-2-AP; PROTEIN-
TECH) or β-actin (mouse monoclonal antibody; sc-81178; Santa
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Cruz) at a dilution of 1:500, for 1 h at 37 1C. The membrane was
washed ﬁve times with 0.1% Tween 20/PBS, followed by an
incubation for 1 h with HRP conjugated goat anti-rabbit secondary
antibody (1:10,000; BA1054, Boster) or HRP conjugated goat anti-
mouse secondary antibody (1:10,000; BA1050, Boster). Following
ﬁve washes with 0.1% Tween 20/PBS, the bands were visualized by
exposure to FluorChem HD2 Imaging System (Alpha Innotech)
after the addition of chemiluminescent substrate (SuperSignals
West Dura Extended Duration Substrate; 34075; Thermo Scientiﬁc
Pierce).The grayscale values of WB bands were analyzed using
software Image J.
Immunoﬂuorescence
To detect the cellular localization of tetherin and HSV-2 glycopro-
teins, transfected cells on 35 mm glass bottom culture dishes were
washed twice with PBS, followed by ﬁxation with 4% (w/v) cold
paraformaldehyde for 30 min at room temperature. Cells were
permeabilized with PBST (PBS-0.2% (v/v) Triton X-100) for 10 min at
room temperature and then blocked with PBS-2% (w/v) BSA for 1 h at
room temperature. Cells were incubated for 1 h at 37 1C with a mouse
monoclonal antibody against FLAG (F1804; Sigma) at a dilution of
1:200, gB (mouse monoclonal antibody; ab6506; Abcam) at a dilution
of 1:200, gD (mouse monoclonal antibody; sc-58154; Santa Cruz) at a
dilution of 1:50 or HSV-2 (sheep polyclonal antibody; PAB13979;
Abnova) at a dilution of 1:200, followed by an incubation for 1 h at
37 1C with a FITC-conjugated goat anti-mouse secondary antibody
(Boster, China) at a dilution of 1:100, a Cy3-conjugated goat anti-
rabbit secondary antibody (Boster, China) at a dilution of 1:100 or a
FITC-conjugated rabbit anti-goat secondary antibody (Boster, China)
at a dilution of 1:100 in PBS-2% (w/v) BSA. To assess the localization of
HSV-2 glycoprotein on cell surface, transfected cells on 35 mm glass
bottom culture dishes were washed twice with PBS, followed by
ﬁxation with 4% (w/v) cold paraformaldehyde without permeabiliza-
tion for 30 min at room temperature, and then incubated for 1 h at
4 1C with a mouse monoclonal antibody against FLAG (F1804; Sigma),
gB (ab6508; Abcam), gD (sc-52425; Santa Cruz) or HSV-2 (PAB13979;
Abnova), followed by an incubation for 1 h at 4 1C with a FITC-
conjugated goat anti-mouse secondary antibody, Cy3-conjugated goat
anti-rabbit secondary antibody or FITC-conjugated rabbit anti-goat
secondary antibody (Boster, China). Cells were washed three times
after each incubation with PBS and then twice with distilled water.
Nuclei were dyed by Hoechst 33258 (Invitrogen). Stained cells were
analyzed using confocal microscopy (PerkinElmer UltraViewVoX)
using a 60 oil objective with 1.5-fold optical zoom and 2.5-fold
digital zoom.
Co-immunoprecipitation
Co-immunoprecipitation assay was carried out using Pierce Cross-
link Immunoprecipitation Kit (26147; Thermo scientiﬁc) according to
the manufacturer’s instructions. For co-immunoprecipitations of
tetherin and HSV-2 glycoproteins, mouse monoclonal antibody
against FLAG (F1804; Sigma) and rabbit polyclonal antibody against
tetherin (11721; NIH AIDS Research and Reference Reagent Program)
were used for pull-down experiments. These two antibodies were
also used for western blot analysis of the immunoprecipitates and
the lysates.
Statistical analysis
All experiments were repeated for at least three times, and the
data are presented as mean7SD unless otherwise speciﬁed. The
difference of mean value was analyzed by a paired Student’s t-test.
Po0.05 was considered statistically signiﬁcant.
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